Passage Bio Inc (PASG)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $13.68M
Last updated: Nov 17, 2026 at 11:06 AM ET
Passage Bio Inc (PASG) Stock Forecast
Analysts expect Passage Bio (PASG) to earn -$14.08 per share in the fiscal year ending Dec 31, 2026. Of 3 analysts, 1 rates the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$11.55.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.67, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 33% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 1 | 33.3% |
| Hold | 2 | 66.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$14.08
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$11.55
- EPS consensus
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$14.08 | -$14.08 to -$14.08 | 1 |
| Dec 31, 2027 | -$11.55 | -$11.55 to -$11.55 | 1 |
Quarterly Estimates
The EPS consensus rises from -$2.60 for the quarter ending Dec 31, 2026 to -$2.33 for the quarter ending Mar 31, 2027.
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.60 | N/A | 5 |
| Mar 31, 2027 | -$2.33 | -$4.06 to -$1.01 | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$11.34.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$14.08 | -$14.08 | -$11.34 | -$11.34 | -$11.34 | N/A |
| Fiscal year ending Dec 31, 2027 | -$11.55 | -$11.55 | -$10.39 | -$10.39 | -$10.39 | N/A |
| Quarter ending Mar 31, 2027 | -$2.33 | -$2.08 | -$1.93 | -$2.03 | -$2.02 | N/A |
Frequently Asked Questions About PASG
What is the PASG stock forecast?
Consensus analyst estimates put Passage Bio's EPS at -$14.08 for the fiscal year ending Dec 31, 2026. The consensus rating from 3 analysts is Hold.
How do analysts rate PASG stock?
Of 3 analysts covering Passage Bio, 0 rate it Strong Buy, 1 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from PASG next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$14.08, with estimates from -$14.08 to -$14.08 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$11.55, with estimates from -$11.55 to -$11.55 from 1 analyst.
How many analysts cover PASG?
3 analysts rate Passage Bio stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
PASG pages: Overview, Earnings, Forecast, Financials, Competitors